by Fred Dumais | Jun 7, 2023 | News Release
MONTREAL, QUEBEC , June 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on...
by Fred Dumais | May 25, 2023 | News Release
Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with prior quarters ENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior year MONTREAL, QUEBEC , May 25, 2023 –...
by Fred Dumais | Apr 28, 2023 | News Release
MONTREAL, QUEBEC , April 28, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the results of the proposals submitted to shareholders at its annual meeting of shareholders held on...
by Fred Dumais | Apr 19, 2023 | News Release
MONTREAL, QUEBEC , April 19, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo’s Chief Executive Officer, will present a corporate overview and provide a...
by Fred Dumais | Mar 15, 2023 | News Release
• Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22 • Fifth consecutive quarter of adjusted gross profit increase at $4.2 million, up 178% over Q1-22 • Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million,...
by Fred Dumais | Mar 9, 2023 | News Release
MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023...
